Study guide

7.6 Therapeutic Drug Monitoring & Glucose Tolerance Testing

NCCT National Certified Phlebotomy Technician NCPT

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: NCPT Exam Overview, Eligibility & Study Strategy

1.1 Exam Facts, Format & Scoring 1.2 Eligibility Pathways, Application & Retake Policy 1.3 Blueprint Study Strategy & Credential Roadmap

2 Chapter 2: Infection Control & Safety (Domain 1 — 15%)

2.1 The Chain of Infection & Breaking Transmission 2.2 Hand Hygiene & Glove Use Standards 2.3 PPE Selection & Donning/Doffing Protocols 2.4 Sharps Safety & Safety-Device Activation 2.5 Isolation Precautions & Biohazard Spill Response 2.6 Cleaning & Disinfecting Equipment and Work Surfaces 2.7 OSHA Bloodborne Pathogens & Post-Exposure Management

3 Chapter 3: Equipment Selection (Domain 2A — 12 items)

3.1 Equipment Quality Verification & Allergy Alternatives 3.2 Venipuncture Equipment & Needle Anatomy 3.3 Winged Infusion Sets (Butterfly) & Syringe Systems 3.4 Capillary Equipment & Lancet Depth Selection 3.5 Bandaging Materials & Post-Collection Patient Care

4 Chapter 4: Patient & Site Preparation (Domain 2B — 13 items)

4.1 Patient Identification Standards 4.2 Requisition Review, Order Clarification & Documentation 4.3 Physiological Factors & Basal State Patient Prep 4.4 Patient Education & Therapeutic Communication 4.5 Venous Site Selection & Prohibited Sites 4.6 Antiseptic Selection & Tourniquet Application

5 Chapter 5: Routine Venipuncture Procedure (Domain 3 — 30%)

5.1 Prioritizing Collections: STAT, Timed & Routine 5.2 Routine Venipuncture: Preparation & Patient Assessment 5.3 Needle Insertion, Collection & Post-Puncture Care 5.4 CLSI Order of Draw & Tube Additive Mechanics 5.5 Fill Volumes, Inversions & Matching Tests to Tubes

6 Chapter 6: Special Patient Populations & Precautions

6.1 Precautions for Patients with Medical Conditions 6.2 Adapting Collection for Pediatric Patients 6.3 Geriatric, Dialysis & Other Difficult-Draw Populations

7 Chapter 7: Capillary & Special Collections

7.1 Capillary Blood Composition, Indications & Contraindications 7.2 Fingerstick Site Selection, Warming & Technique 7.3 CLSI GP42 Capillary Order of Draw & Blood Gas Collection 7.4 Neonatal Heelstick & Newborn Metabolic Screening 7.5 Blood Culture Collection Protocols & Timing 7.6 Therapeutic Drug Monitoring & Glucose Tolerance Testing 7.7 Point-of-Care Testing Procedures

8 Chapter 8: Specimen Handling, Processing & Non-Blood Specimens

8.1 Specimen Mixing & Mandatory Bedside Labeling 8.2 Assessing Specimen Suitability & Rejection Criteria 8.3 Temperature-, Light- & Time-Sensitive Specimen Handling 8.4 Specimen Processing: Centrifugation, Aliquoting & Storage 8.5 Non-Blood Specimen Collection & Patient Instruction 8.6 Processing Non-Blood Specimens & Routing to Laboratory Departments

9 Chapter 9: Collection Complications & Troubleshooting (Domain 4 — 15%)

9.1 Vasovagal Syncope: Recognition & Emergency Response 9.2 Seizures, Nausea, Petechiae & Allergic Reactions 9.3 Nerve Injury, Hematomas & Accidental Arterial Puncture 9.4 Technical Troubleshooting & the Two-Attempt Rule 9.5 Hemolysis & Hemoconcentration 9.6 IV Contamination & Analytical Interference

10 Chapter 10: Law, Ethics & Regulatory Standards (Domain 5 — 15%)

10.1 Civil Law, Torts, Negligence & Standard of Care 10.2 Patient Consent, the AHA Bill of Rights & Refusal 10.3 HIPAA Privacy Rule & Permitted Disclosures 10.4 Forensic Chain of Custody & Blood Alcohol Collection 10.5 Workplace Safety Regulation: OSHA, SDS, NFPA & Fire Response 10.6 CLIA ’88, Quality Assurance & Quality Control 10.7 Reportable Incidents, Risk Management & Error Disclosure

11 Chapter 11: Comprehensive Review & Clinical Practice Scenarios

11.1 Critical Order of Draw & Additive Reference Summary 11.2 Clinical Decision Scenarios & Troubleshooting Drills 11.3 Exam-Day Strategy & Professional Recertification

7.6 Therapeutic Drug Monitoring & Glucose Tolerance Testing

Key Takeaways Explain This Topic AI

A trough level is drawn immediately before the next scheduled dose; a peak is drawn at a drug-specific interval after administration.

Trough levels assess toxicity risk and peak levels assess therapeutic efficacy.

Every therapeutic drug level must be documented with the exact collection time and the time of the last dose.

GTT timing starts when the patient finishes drinking the glucose load, not when they begin.

A patient who vomits the glucose load during a GTT requires the test to be stopped and the provider notified.

Last updated: August 2026

7.6 Therapeutic Drug Monitoring & Glucose Tolerance Testing

Quick Answer: Therapeutic Drug Monitoring (TDM) ensures medications with narrow therapeutic indexes remain effective without toxicity. Trough levels are drawn immediately before the next dose (within 15–30 min) ; Peak levels are drawn at maximum concentration ( IV: 30 min post-infusion , IM: 1 hr , Oral: 1–2 hr ). Glucose Tolerance Testing (GTT) begins with a fasting baseline draw; if fasting glucose is >200 mg/dL, halt the test and notify the physician . The timer starts the moment the patient finishes the Glucola drink (within 5 minutes). Chilled specimens ( Ammonia, Lactic Acid [no tourniquet/no fist pumping], ABGs, ACTH, Renin, PTH ) require immersion in a crushed ice-and-water slurry (1°C–5°C) to halt metabolism. Warm specimens ( Cold Agglutinins, Cryoglobulins ) require pre-warmed 37°C tubes and body-temperature transport. Photosensitive specimens ( Bilirubin, Vitamins A/B6/B12, Beta-carotene, Porphyrins ) must be wrapped in aluminum foil or collected in amber tubes ; light degrades bilirubin by up to 50% per hour .

Therapeutic Drug Monitoring (TDM)

Therapeutic Drug Monitoring (TDM) represents the precise clinical coordination between pharmacy, nursing, and phlebotomy to measure drug concentrations in serum or plasma. TDM is indicated for pharmacological agents with a narrow therapeutic window (therapeutic index) —where the margin between effective clinical therapy and severe toxicity is dangerously small. THERAPEUTIC DRUG MONITORING (TDM) SPECTRUM

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ [ Sub-Therapeutic ] [ OPTIMAL THERAPEUTIC RANGE ] [ TOXIC ] │
  • │ (Clinical Failure) │ Maximum Efficacy / Safety │ (Organ Dmg)│
  • ├──────────────────────────┼───────────────────────────────┼─────────────┤
  • │ ▲ ▲ │
  • │ │ │ │
  • │ TROUGH LEVEL PEAK LEVEL │
  • │ (Drawn 15-30 min BEFORE) (Drawn Post-Admin) │
  • └────────────────────────────────────────────────────────────────────────┘
  • Commonly Monitored Medications

Drug Category Generic / Brand Name Clinical Indication Toxicity Risks

Glycopeptide Antibiotics Vancomycin (Vancocin) MRSA, severe gram-positive sepsis Nephrotoxicity, ototoxicity, Red Man syndrome

Aminoglycoside Antibiotics Gentamicin , Tobramycin , Amikacin Gram-negative bacilli sepsis Irreversible ototoxicity, acute tubular necrosis

Cardiac Glycosides Digoxin (Lanoxin) Heart failure, atrial fibrillation Fatal arrhythmias, visual halos, hyperkalemia

Anticonvulsants Phenytoin (Dilantin), Carbamazepine Epilepsy, grand mal seizures Ataxia, nystagmus, lethargy, bone marrow failure

  • Mood Stabilizers Lithium (Eskalith) Bipolar affective disorder Renal tubular damage, tremors, seizures, coma
  • Bronchodilators Theophylline (Theo-24) Severe asthma, COPD Tachycardia, status epilepticus, cardiac arrest

Immunosuppressants Cyclosporine , Tacrolimus (FK506) Organ transplant rejection prophylaxis Renal failure, hypertension, neurotoxicity

  • Trough vs. Peak Collection Protocols TDM COLLECTION TIMING RULES
  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ 1. TROUGH LEVEL (Lowest Blood Concentration) │
  • │ • Drawn IMMEDIATELY BEFORE the next scheduled dose. │
  • │ • Standard window: Within 15 to 30 minutes prior to administration. │
  • │ • Purpose: Confirms adequate drug clearance; prevents toxicity. │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ 2. PEAK LEVEL (Highest Blood Concentration) │
  • │ • Drawn at estimated highest tissue/vascular concentration. │
  • │ • Intravenous (IV) Route: Exactly 30 MINUTES after infusion finishes│
  • │ • Intramuscular (IM) Route: Exactly 1 HOUR (60 minutes) post-injec. │
  • │ • Oral (PO) Route: Exactly 1 to 2 HOURS after ingestion. │
  • │ • Purpose: Verifies drug reaches therapeutic bactericidal levels. │
  • └────────────────────────────────────────────────────────────────────────┘

Important

Critical Coordination Protocol: Never draw a peak level until confirming the exact minute the IV infusion finished with the patient's primary nurse. If an infusion was delayed or ran slowly, drawing at the originally scheduled time produces a falsely elevated peak that causes inappropriate dosage reduction. Always record the exact collection time and tube labeling metadata in the LIS.

Oral Glucose Tolerance Testing (GTT / OGTT)

Oral Glucose Tolerance Testing evaluates the endocrine pancreas's ability to secrete insulin and clear a standardized glucose challenge from the bloodstream over time. CLINICAL PROTOCOLS FOR GTT / OGTT

  • ┌───────────────────────┬──────────────┬─────────────────────────────────┐
  • │ Diagnostic Test Type │ Glucola Dose │ Blood Collection Intervals │
  • ├───────────────────────┼──────────────┼─────────────────────────────────┤
  • │ 1-Hour Gestational │ 50 Grams │ Non-fasting; 1 hour post-drink │
  • │ Screening Challenge │ (Glucola) │ (Threshold: ≥130–140 mg/dL) │
  • ├───────────────────────┼──────────────┼─────────────────────────────────┤
  • │ 2-Hour Adult / Type 2 │ 75 Grams │ Fasting, 1-Hour, 2-Hour │
  • │ Diagnostic OGTT │ (Glucola) │ (Diabetes: Fasting ≥126 / 2hr ≥200)│
  • ├───────────────────────┼──────────────┼─────────────────────────────────┤
  • │ 3-Hour Diagnostic │ 100 Grams │ Fasting, 1-Hour, 2-Hour, 3-Hour │
  • │ Gestational OGTT │ (Glucola) │ (Diagnostic confirmation of GDM)│
  • └───────────────────────┴──────────────┴─────────────────────────────────┘
  • Step-by-Step GTT Protocol & The Hyperglycemia Safety Rule STEP-BY-STEP GTT WORKFLOW
  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Step 1: Verify 8–12 hr fast & high-carb diet (150g/day x 3 days). │
  • │ Step 2: Draw FASTING baseline blood sample. │
  • │ Step 3: EVALUATE FASTING GLUCOSE: If >200 mg/dL, STOP & NOTIFY MD! │
  • │ Step 4: Administer Glucola drink (patient drinks within 5 MINUTES). │
  • │ Step 5: START TIMER THE EXACT MOMENT THE DRINK IS FINISHED! │
  • │ Step 6: Collect blood at exact timed intervals (1-hr, 2-hr, 3-hr). │
  • │ Step 7: Enforce strict patient resting rules (no food, smoking, gum). │
  • └────────────────────────────────────────────────────────────────────────┘

Pre-Test Preparation: Patient must maintain an unrestricted diet containing at least 150 grams of carbohydrates per day for 3 consecutive days prior to testing. Patient must be in a complete fasting state for 8 to 12 hours before the baseline draw. No smoking, coffee, or vigorous exercise.

Fasting Baseline Collection: Draw a fasting baseline blood specimen (Sodium Fluoride Gray top or Serum Separator Gold top).

THE FASTING HYPERGLYCEMIA SAFETY RULE:

Check the fasting glucose level immediately (or via point-of-care rapid glucose analyzer).

If fasting glucose is >200 mg/dL (or >140 mg/dL per institutional protocol): DO NOT ADMINISTER THE GLUCOSE DRINK.

Rationale: Administering a concentrated 75g or 100g sugar load to a severely hyperglycemic patient can precipitate acute Diabetic Ketoacidosis (DKA) or Hyperosmolar Hyperglycemic State (HHS) . Immediately notify the ordering physician and cancel the glucose challenge.

Glucola Ingestion: If fasting glucose is safe, the patient consumes the standardized commercial glucose drink (Glucola) within 5 minutes .

Timing Initiation: The timing clock starts THE EXACT MOMENT THE PATIENT FINISHES DRINKING the entire beverage (not when drinking begins).

Timed Blood Draws: Collect blood specimens at exact intervals (e.g., exactly at 1 hour, 2 hours, and 3 hours post-ingestion). Label each tube with the exact draw time and interval designation (e.g., "2-Hour Timed Draw" ).

Patient Behavioral Restrictions:

Patient must remain seated quietly in the waiting area throughout the entire test.

No walking, physical exertion, eating food, chewing gum, mints, or smoking.

Small sips of plain water are permitted to maintain hydration.

Vomiting Protocol: If the patient vomits the Glucola beverage at any point during the test, the test is invalidated . The draw must be terminated immediately, the physician notified, and the test rescheduled for another day.